|
COPYRIGHT 2003 International Medical News Group
WILMINGTON, DEL. -- Despite the controversy following the death of University of Pennsylvania patient Jesse Gelsinger, little has changed in the regulation of clinical trials, according to Arthur Caplan, Ph.D., director of the Center for Bioethics at the university in Philadelphia.
The long-term impact of Mr. Gelsinger's death on efforts to better monitor human experimentation has been "absolutely nothing," Dr. Caplan said at the annual meeting of the American Society of Law, Medicine, and Ethics. "In fact, I'd argue that in some ways human subject protection is worse than it was when Jesse died."
In September 1999, Mr. Gelsinger...
Read the full article for free courtesy of your local library.
|
Bookmark this article
Print this article
Link to this article
Email this article
Digg It!
Add to del.icio.us
RSS
